Through in depth, due diligence, DisruptorSeeker hopes to uncover hidden opportunities in the small and micro cap space. DisruptorSeeker has learned, however, that many of what look like gems on the surface often have coal underneath the shiny facade. As a result, DisruptorSeeker is happy to look at both long and short candidates. DisruptorSeeker looks for truly transformative technology, good management with incentive aligned with shareholders, and near term catalysts for realizing a market beating return.
Adam Gefvert is the head researcher for White Diamond Research, a research firm for hedge funds and high net worth individuals. Primarily a short seller, he has saved investors millions of dollars by exposing highly overvalued small cap stocks. He has a 90%+ success rate with his Seeking Alpha short ideas. He specializes in technology, energy, and biotech stocks, because those are the sectors with the greatest valuation inefficiencies.
You can follow Adam on twitter @shiningboy
Fama and French proved out that Asset Allocation accounts for 96% of typical investment returns. I need to constantly remind myself that it is about asset allocation, not individual company picks. Buffett is an asset allocator, not just a stock picker.
I have decided to pursue the Magic Formula methodology of stock selections. I put on a twist that I got from reading Warren Buffet. He suggests that you invest at the lowest market cap you can. He can’t buy micro caps in BRK.B since they won’t move the needle on his portfolio. I can and will.
I am starting to invest in small-cap pharmaceutical stocks, and maintain my own portfolio. I am mostly learning about upcoming newer drugs and technologies, while following up with catalysts.
Stirling Capital Management is a client focused and performance oriented investment firm. We scour the globe for opportunity in any asset class with asymmetrical risk versus return characteristics.
I have traveled through the abyss of Chinese reverse mergers and lived to tell about it. Primarily trade small caps: bio-pharma, commodity related, low float value, and US listed Chinese stocks.
My name is Mark B. Spiegel and I'm the Managing Member of Stanphyl Capital Management LLC. I can be reached at: mark (at) stanphylcap (dot) com. My Twitter feed is @markbspiegel